Last reviewed · How we verify
Chlorthalidone with potassium chloride
Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, while potassium chloride supplementation replaces electrolytes lost during diuresis.
Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, while potassium chloride supplementation replaces electrolytes lost during diuresis. Used for Hypertension, Edema associated with congestive heart failure or renal disease.
At a glance
| Generic name | Chlorthalidone with potassium chloride |
|---|---|
| Also known as | hygroton |
| Sponsor | Brigham and Women's Hospital |
| Drug class | Thiazide-like diuretic with potassium supplement |
| Target | Sodium-chloride cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Chlorthalidone blocks the sodium-chloride cotransporter in the kidney's distal convoluted tubule, promoting urinary sodium and water excretion to reduce blood volume and blood pressure. The combination with potassium chloride mitigates hypokalemia, a common adverse effect of thiazide diuretics, by replacing potassium lost in urine.
Approved indications
- Hypertension
- Edema associated with congestive heart failure or renal disease
Common side effects
- Hypokalemia
- Hyperglycemia
- Hyperuricemia
- Hyponatremia
- Dizziness
- Headache
Key clinical trials
- Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia (PHASE2)
- Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity (PHASE4)
- Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment (PHASE4)
- Arterial Stiffness and Blood Pressure (NA)
- Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate (NA)
- Spironolactone in CKD Enabled by Chlorthalidone: PILOT (PHASE2)
- Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease (PHASE4)
- An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: